Non-Small Cell Lung Cancer

This is a common type of lung cancer. It's called 'non-small cell' because the cancer cells look different from the small cell type. It's the most frequent type of lung cancer, making up about 85% of cases.

Condition

What people with Non-Small Cell Lung Cancer report

Every report comes from a Lived member, sent anonymously.

Have you tried Keytruda (Pembrolizumab) for Non-Small Cell Lung Cancer?

NameHow it went

About Non-Small Cell Lung Cancer

What It Is

Non-small cell lung cancer (NSCLC) is a cancer that starts in the cells lining the lungs and their airways. It is the more common of the two main types of lung cancer, accounting for about 80 to 85 percent of cases. The other type, small cell lung cancer, grows and is treated differently, so knowing which type someone has matters from the start. NSCLC is an umbrella term for several subtypes, named for how the cancer cells look under a microscope. Adenocarcinoma, which begins in cells that make mucus, is the most common. Squamous cell carcinoma starts in the flat cells lining the airways and often sits near a main airway in the center of the chest. Large cell carcinoma is less common. These subtypes are grouped together because their treatment and outlook are often similar. Early lung cancer often causes no symptoms and is sometimes found on a scan done for another reason. When symptoms do appear, they can include a cough that won't go away or keeps getting worse, coughing up blood, chest pain, hoarseness, shortness of breath, tiredness and weight loss without trying. Because many people have no symptoms until the cancer has spread, it is often diagnosed at a later stage.

Causes & Risk Factors

Lung cancer develops when changes in the DNA of lung cells let them grow and divide out of control. Most risk factors do not cause the cancer directly. Instead, they raise the chance of that DNA damage building up over time. Smoking, now or in the past, is the most important risk factor. Risk rises the earlier someone starts, the more they smoke each day and the more years they smoke. Quitting lowers risk compared with continuing, although it stays higher than in people who never smoked. Other contributors include secondhand smoke, radon gas in homes, workplace exposure to asbestos and certain metals, earlier radiation treatment to the chest, air pollution and a family history of lung cancer. NSCLC is not only a smoker's disease. Adenocarcinoma is the most common lung cancer in people who have never smoked, and it occurs more often in women and in younger people than other types do. Having a risk factor does not mean someone will develop lung cancer, and some people are diagnosed without any known risk factor.

How It's Diagnosed

Lung cancer is usually first suspected because of symptoms or a spot seen on a chest X-ray or CT scan. A CT (computed tomography) scan combines many X-ray images into detailed cross-sections of the chest. Imaging can show where something looks abnormal, but only a biopsy confirms cancer. The sample may be taken with a thin needle through the chest wall, through a flexible scope passed into the airways (bronchoscopy), or during a small surgical procedure. A pathologist then examines it under a microscope to confirm NSCLC and identify the subtype. Two further questions shape almost every treatment decision. The first is stage, meaning how large the tumor is and whether it has spread. Staging often uses a PET-CT scan (positron emission tomography combined with CT), which highlights areas that absorb extra sugar as cancer cells tend to, along with magnetic resonance imaging (MRI) of the brain and sometimes biopsies of lymph nodes in the chest. Stage I means a tumor confined to the lung with no lymph node spread; stage IV means the cancer has reached distant sites such as the brain, bones, liver or the other lung. The second is biomarker testing of the tumor. This looks for gene changes such as EGFR (epidermal growth factor receptor) and ALK (anaplastic lymphoma kinase), and for PD-L1 (programmed death-ligand 1), a protein that tumors can use to hide from the immune system. The results show who is likely to benefit from targeted drugs or immunotherapy. Breathing tests (pulmonary function tests) measure how well the lungs work, which matters when surgery is being considered. For people at high risk, screening can find lung cancer before symptoms start. The US Preventive Services Task Force recommends a yearly low-dose CT scan for adults aged 50 to 80 who have a 20 pack-year smoking history and still smoke or quit within the past 15 years. One pack-year equals smoking a pack a day for a year, so 20 pack-years could mean a pack a day for 20 years or two packs a day for 10.

Treatment Options

Treatment depends mainly on the stage, the subtype, the tumor's gene changes, and a person's overall health and preferences, and many people receive more than one kind. Early-stage cancer can sometimes be removed completely. For most people with NSCLC, though, current treatments do not cure the cancer, and the aim is to control it and its symptoms for as long as possible. For stage I and many stage II cancers, surgery is the main treatment. This usually means removing one lobe of the lung (a lobectomy) or a smaller section, and occasionally a whole lung. People who cannot have surgery, or choose not to, may have stereotactic body radiation therapy, which aims high, precisely focused doses of radiation at the tumor over a small number of sessions. After surgery, chemotherapy, immunotherapy or a targeted drug may be added to lower the chance of the cancer returning. Some people receive chemotherapy with immunotherapy before surgery instead. Stage III cancers have reached lymph nodes in the chest or nearby structures, and treatment usually combines approaches. When surgery is not possible, a common plan is chemotherapy given together with radiation, followed by a course of immunotherapy. For stage IV cancer, or cancer that comes back, treatment is mainly with medicines chosen according to the biomarker results. Targeted therapies block the specific abnormal protein driving the cancer and only work when that change is present, which is why testing comes first. For example, osimertinib (Tagrisso) is a daily pill for cancers with certain EGFR changes, and alectinib (Alecensa) is one of several pills for ALK-positive cancers. Immunotherapy drugs called checkpoint inhibitors, such as pembrolizumab (Keytruda), are given by infusion and release a brake on the immune system so it can attack cancer cells. They are often combined with chemotherapy, which remains part of treatment for many people. Each option has trade-offs. Surgery involves a hospital stay of about 1 to 7 days and a recovery of weeks to months. Chemotherapy lowers white blood cell counts for part of each cycle, which raises the risk of infection. Targeted drugs commonly cause skin problems, diarrhea and tiredness. Immunotherapy can lead the immune system to attack healthy organs such as the lungs, bowel, liver or hormone glands. These reactions are uncommon but can be serious, and treating them early with steroid medicines makes a difference. Palliative care, a specialty focused on relieving symptoms such as breathlessness, pain and fatigue, can start at diagnosis alongside cancer treatment. In a randomized trial of people with newly diagnosed advanced NSCLC, adding it early improved quality of life and mood. Quitting smoking helps the body heal and respond to treatment, and clinical trials of new treatments are open for every stage.

What to Expect

The outlook for NSCLC varies widely with stage. As a population guide, about two in three people whose cancer is still confined to the lung at diagnosis are alive five years later. That falls to about four in ten when it has reached nearby lymph nodes or tissues, and about one in eight when it has spread to distant organs. These figures come from people diagnosed between 2015 and 2021, so they do not fully reflect newer treatments, and they cannot predict how any one person will do. After surgery for early-stage disease, people whose lungs were otherwise healthy can usually return to their normal activities over time, even if a lobe or a whole lung was removed. Those who also have emphysema or chronic bronchitis may notice shortness of breath with some activities. Follow-up continues for years because the cancer can come back. Many doctors recommend visits, which may include CT scans and blood tests, about every three months for the first couple of years, about every six months for several years after that, then at least yearly. With advanced NSCLC, treatment is often ongoing. Scans and other tests are repeated regularly to see whether it is working, and the plan is adjusted or switched when it stops helping or side effects become too much. Tiredness, breathlessness and the emotional weight of the diagnosis are common for patients and the people close to them. Palliative care, counseling and practical help with daily tasks can ease that load, and it helps to raise these concerns early rather than waiting for a crisis.

When to Seek Help

See a doctor soon about a cough that lasts or keeps getting worse, coughing up blood or rust-colored phlegm, chest pain, hoarseness, shortness of breath or weight loss without trying. These symptoms usually have other causes, but finding lung cancer earlier makes effective treatment more likely. If you are between 50 and 80 and have smoked heavily, ask whether yearly screening is right for you. During treatment, call your cancer care team right away for a fever of 100.5°F (38°C) or higher, or for chills, because infections can become life threatening when white blood cell counts are low. If you are on immunotherapy, report any new symptom promptly, especially a new cough or breathlessness, or diarrhea. Swelling of the face, neck or arms, which can mean a tumor is pressing on a large vein in the chest, also needs same-day attention. Get emergency care for a seizure, sudden weakness or numbness in an arm or leg, or face and neck swelling with severe trouble breathing or confusion.

Questions to Ask Your Doctor

  1. 1.What stage and subtype is my cancer, and what is the realistic goal of treatment?
  2. 2.Has my tumor been tested for gene changes and PD-L1, and how do the results change my options?
  3. 3.What benefits and main side effects should I expect from the treatment you recommend, compared with the alternatives?
  4. 4.Would a second opinion or a clinical trial be worth considering at this point?
  5. 5.How can palliative care and other support help me manage symptoms during treatment?

Last reviewed • Oct 2026

Educational content, not medical advice.